Amedeo Smart

Free Medical Literature Service


 

Amedeo

Schizophrenia

  Free Subscription

04.05.2026

1 Br J Psychiatry
1 Brain Res
1 Cereb Cortex
2 Mol Psychiatry
2 Neuropsychopharmacology
4 Psychiatry Res
7 Psychol Med
5 Schizophr Res



    Br J Psychiatry

  1. WILLIAMS R, Penington E, Gupta V, Rickett M, et al
    From early intervention in psychosis to intensive care: correlates of restrictive psychiatric practice in a national retrospective cohort study.
    Br J Psychiatry. 2026 Apr 30:1-11. doi: 10.1192/bjp.2026.10637.
    >> Share


    Brain Res

  2. CASSOL G, de Souza MA, da Silva Fiorin F
    Physical exercise as a non-pharmacological adjunct in schizophrenia: Effects on molecular and biochemical parameters.
    Brain Res. 2026 Apr 25:150344. doi: 10.1016/j.brainres.2026.150344.
    >> Share


    Cereb Cortex

  3. CHUNG Y, Bazmi HH, Lewis DA, Chung DW, et al
    Disrupted ErbB4 splicing with region-specific severity across the cortical visuospatial working memory network in schizophrenia.
    Cereb Cortex. 2026;36:bhag045.
    >> Share


    Mol Psychiatry

  4. REICHENBERG A, Kahn RS
    Cognitive impairment preceding the onset of the first psychosis episode in schizophrenia.
    Mol Psychiatry. 2026 Apr 28. doi: 10.1038/s41380-026-03625.
    >> Share

  5. WANG L, Xu K, Liao Y, Luo Y, et al
    Astrocytic connexin 43 hemichannel dysregulation drives prefrontal circuit dysfunction and schizophrenia-like behaviors.
    Mol Psychiatry. 2026 Apr 27. doi: 10.1038/s41380-026-03621.
    >> Share


    Neuropsychopharmacology

  6. CHANG X, Bryant L, Mena Ortega S, Howes O, et al
    A frontotemporal dementia-like phenotype in schizophrenia: links to striatal dopamine and iron accumulation.
    Neuropsychopharmacology. 2026 Apr 25. doi: 10.1038/s41386-026-02426.
    >> Share

  7. KHIN NA, Fan RH, Ge T, Klein HS, et al
    A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study.
    Neuropsychopharmacology. 2026 Apr 24. doi: 10.1038/s41386-026-02410.
    >> Share


    Psychiatry Res

  8. LEBOVITZ JG, Kittleson AR, Sloan AF, Torregrossa LJ, et al
    Longitudinal relationships among dissociation, paranoia, and anxiety in a clinical sample of individuals with schizophrenia-spectrum conditions.
    Psychiatry Res. 2026;362:117174.
    >> Share

  9. AHMAD I, Wang Y, Guo S, Cui L, et al
    Exploring schizophrenia-associated image-derived digital phenotypes in dual-energy X-ray densitometer scans of non-dominant distal forearm: An explainable machine-learning framework.
    Psychiatry Res. 2026;362:117186.
    >> Share

  10. SONG X, Feng T, Lin H, Qian H, et al
    A real-world pharmacovigilance study of Xanomeline-Trospium events in the FDA adverse event reporting system (FAERS).
    Psychiatry Res. 2026;361:117162.
    >> Share

  11. HUBBARD LA, Zhang JN, Moore RC, Depp CA, et al
    Does hearing voices make you nervous? An ecological momentary assessment investigation of momentary emotional responses to the occurrence of psychotic symptoms.
    Psychiatry Res. 2026;361:117098.
    >> Share


    Psychol Med

  12. CHU MY, Zhu NJ, Li SB, Wang Y, et al
    Characterizing executive dysfunctions in patients with schizo-obsessive comorbidity: comparing schizophrenia with obsessive-compulsive disorder.
    Psychol Med. 2026;56:e116.
    >> Share

  13. CHRISTENSEN MJ, Vernal DL, Jeppesen UN, Hjorthoj C, et al
    Treatment effect modifiers of virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: an exploratory moderator analysis of clinical and demographic characteristics in the FaceYourFears trial
    Psychol Med. 2026;56:e117.
    >> Share

  14. ADANE AA, Dadi A, Jegnie A, Tadesse AW, et al
    Cognitive performance in offspring of parents with severe mental illness: a meta-analysis.
    Psychol Med. 2026;56:e115.
    >> Share

  15. VAN DER WEIJDEN-GERMANN M, van Haren NEM, Meijer MN, Broer MI, et al
    Unraveling reward processing in schizophrenia and bipolar disorder: a multilevel examination of the positive valence system.
    Psychol Med. 2026;56:e112.
    >> Share

  16. FORTE MF, Segura AG, Serra-Navarro M, Mezquida G, et al
    Cognitive reserve in non-affective first-episode psychosis: contributions of polygenic scores, early clinical features, and environment.
    Psychol Med. 2026;56:e114.
    >> Share

  17. HU Q, Jiao X, Ding Y, Wei Y, et al
    The effects of rTMS over orbitofrontal cortex on cognitive functions in first-episode schizophrenia.
    Psychol Med. 2026;56:e119.
    >> Share

  18. CHANG WC, Hung DP, Chen MH, Su TP, et al
    Distinct and common subcortical functional connectivity revealed across three major psychiatric disorders.
    Psychol Med. 2026;56:e109.
    >> Share


    Schizophr Res

  19. VAN DER WALT K, Campbell M, Susser E, Jonker D, et al
    Distinct attentional deficits after catatonia in schizophrenia.
    Schizophr Res. 2026;294:116-123.
    >> Share

  20. KU BS, Arrant EJ, Walker EF
    Neighborhood Characteristics and Psychosis Risk Across Development.
    Schizophr Res. 2026;294:96-98.
    >> Share

  21. HAZELTON K, Stein A, Gallardo M, Fernandes D, et al
    Trajectories of crystallized cognition over 28 years: Testing the neurodegenerative hypothesis of schizophrenia.
    Schizophr Res. 2026;294:110-115.
    >> Share

  22. DE OLIVEIRA CA, Soares MVR, de Pinho CSN, Pinto JP, et al
    A high-resolution plasma proteomic framework for stratifying treatment resistance and ultra-resistance in schizophrenia.
    Schizophr Res. 2026;294:86-95.
    >> Share

  23. ANTENS MHH, Kamperman AM, van Aken BC, Castelein S, et al
    Intellectual functioning and personal recovery in individuals with schizophrenia spectrum disorder.
    Schizophr Res. 2026;294:76-85.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016